folfirinox: Clinical Trials

12 trials of folfirinox, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4 completed, 4 unknown, 2 recruiting, 1 active not recruiting. 12 Phase 3, 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 312Completed 4, Unknown 4, Recruiting 2, Active not recruiting 1, Terminated 1
Phase 23Unknown 2, Completed 1

Follow folfirinox: new trials by email Literature Review of folfirinox trials Research Report on folfirinox

Trials (filtered) newest first · largest first

All 12 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Personalizing Chemotherapy Selection After Surgery for Patients With Stage III Colorectal Cancer Using a Blood Test
Capecitabine, Oxaliplatin, Folfirinox - Colorectal Cancer
Phase 3Active not recruitingUNICANCER24502026-07-202026-07-22
Standard or Prolonged Neoadjuvant Chemotherapy Before Surgery for BR/LAPC
FOLFIRINOX or gemcitabine-nab-paclitaxel - Locally Advanced Pancreatic Adenocarcinoma, Borderline Resectable Pancreatic Carcinoma
Phase 3RecruitingSahlgrenska University Hospital4322023-10-182024-12-03
NeoFOL-R Trial (Perioperative Versus Adjuvnat FOLFIRINOX in Resectable Pancreatic Cancer)
Folfirinox - Resectable Pancreatic Cancer, Neoadjuvant Chemotherapy
Phase 3RecruitingSeoul National University Hospital6092023-04-012024-11-27
Survival Analysis After Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer and Risk Factors
Folfirinox and Stereotactic Body Radiotherapy - Pancreatic Adenocarcinoma, Pancreatic Cancer Resectable
Phase 2 / Phase 3UnknownInstituto de investigación e innovación biomédica de Cádiz1162022-04-152022-08-09
Timing of Start of systemIc Treatment for Asymptomatic Metastasized Pancreatic Cancer
Folfirinox - Metastatic Pancreas Cancer
Phase 3UnknownAcademisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)1842021-04-222021-05-24
Brazilian Total Neoadjuvant Therapy Trial
Folfirinox - Colorectal Neoplasms
Phase 3UnknownHospital Israelita Albert Einstein1502020-02-202023-10-11
Evaluation of Efficacy and Safety of Neoadjuvant Treatment With Pamrevlumab in Combination With Chemotherapy (Either Gemcitabine Plus Nab-paclitaxel or FOLFIRINOX) in Participants With Locally Advanced, Unresectable Pancreatic Cancer
Pamrevlumab + Gemcitabine + Nab-paclitaxel or Pamrevlumab + FOLFIRINOX, Placebo + Gemcitabine + Nab-paclitaxel or Placebo + FOLFIRINOX - Pancreatic Cancer Non-resectable
Phase 3CompletedKyntra Bio2842019-05-102024-11-05
Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas
CPI 613, mFolfirinox, Folfirinox - Pancreatic Cancer Metastatic
Phase 3CompletedCornerstone Pharmaceuticals5282018-11-092023-01-03
Induction Chemotherapy, FOLFIRINOX Followed With Concurrent Capecitabine and Radiation Therapy in Inoperable Locally Advanced Cancer of the Pancreas
FOLFIRINOX + CRT - Cancer of Pancreas
Phase 2 / Phase 3UnknownAssiut University12014-10-012014-12-08
Immunotherapy Study in Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer
FOLFIRINOX, Algenpantucel-L Immunotherapy, 5-FU Chemoradiation - Pancreatic Cancer, Pancreatic Carcinoma Non-resectable
Phase 3TerminatedNewLink Genetics Corporation3022013-05-012020-05-28
Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy
Induction chemotherapy with gemcitabine or FOLFIRINOX, Radiotherapy, 28 x 1.8 Gy, Chemotherapy, gemcitabine - Pancreatic Cancer
Phase 3CompletedUniversity of Erlangen-Nürnberg Medical School8302013-04-042024-04-11
Intensified Chemotherapy in CRC After Resection of Liver Metastases
FOLFIRI, FOLFOX-4, FOLFIRI-HD - Colorectal Cancer, Liver Metastases
Phase 2 / Phase 3CompletedInstitut du Cancer de Montpellier - Val d'Aurelle1242004-04-012026-02-05

Conditions studied

Pancreatic Neoplasms (5)  ·  Colorectal Neoplasms (3)  ·  Rectal Neoplasms (1)

Sponsors

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) (1)  ·  Assiut University (1)  ·  Cornerstone Pharmaceuticals (1)  ·  Hospital Israelita Albert Einstein (1)  ·  Institut du Cancer de Montpellier - Val d'Aurelle (1)  ·  Instituto de investigación e innovación biomédica de Cádiz (1)  ·  Kyntra Bio (1)  ·  NewLink Genetics Corporation (1)  ·  Sahlgrenska University Hospital (1)  ·  Seoul National University Hospital (1)  ·  UNICANCER (1)  ·  University of Erlangen-Nürnberg Medical School (1)

Countries

France (4)  ·  Germany (3)  ·  South Korea (3)  ·  United States (3)  ·  Belgium (2)  ·  Israel (2)  ·  Spain (2)  ·  Sweden (2)  ·  Austria (1)  ·  Brazil (1)  ·  Canada (1)  ·  China (1)  ·  Egypt (1)  ·  Italy (1)  ·  Netherlands (1)

Top investigators

Diogo Gomes, MD (1)  ·  Elena Rangelova, PhD (1)  ·  Philip A Philip, MD, PhD, FRCP (1)  ·  Rainer Fietkau, MD (1)  ·  Wooil Kwon (1)

Results publications

PMID 23955585, PMID 31512497, PMID 31640628, PMID 33630475, PMID 37678921, PMID 39088774, PMID 40802908

NIH funding

2009 (1)